Items where authors include "Corcia, P."

Article

Costello, E. orcid.org/0000-0001-8620-9531, De Vocht, J., Beswick, E. et al. (29 more authors) (2025) Neuropsychological assessment practices in PRECISION-ALS: challenges and opportunities for harmonization. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. ISSN 2167-8421

McFarlane, R. orcid.org/0000-0001-7380-4219, Opie-Martin, S., Caravaca Puchades, A. et al. (26 more authors) (2025) Clinical trajectories of genetic variants in ALS: a European observational study within PRECISION-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26 (sup 1). pp. 41-49. ISSN 2167-8421

McDonough, H., McFarlane, R. orcid.org/0000-0001-7380-4219, Caravaca Puchades, A. et al. (26 more authors) (2025) Examining changing working status and caregiver assistance in amyotrophic lateral sclerosis (ALS) using large-scale European databases as part of PRECISION-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26 (sup 1). pp. 20-29. ISSN 2167-8421

Caravaca Puchades, A., McDonough, H.E., Al-Chalabi, A. et al. (26 more authors) (2025) Mapping the natural history of amyotrophic lateral sclerosis: time-to-event analysis of clinical milestones in the pan-European, population-based PRECISION-ALS cohort. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26 (sup1). pp. 8-19. ISSN 2167-8421

van Eijk, R.P.A. orcid.org/0000-0002-7132-5967, Weemering, D.N. orcid.org/0009-0005-4182-3294, Opie-Martin, S. et al. (27 more authors) (2025) Natural history of the revised ALS functional rating scale and its association with survival: the PRECISION-ALS Extant Study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26 (sup 1). pp. 30-40. ISSN 2167-8421

Vasta, R., Ombelet, F., Hobin, F. et al. (26 more authors) (2025) Real-world prognostic role of riluzole use in ALS: a multi-center study from PRECISION-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26 (sup1). pp. 50-60. ISSN 2167-8421

Bensimon, G., Leigh, P.N., Tree, T. et al. (50 more authors) (2025) Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial. The Lancet, 405 (10492). pp. 1837-1850. ISSN 0140-6736

Sennfält, S., Al-Chalabi, A., Caravaca Puchades, A. et al. (26 more authors) (2025) Respiratory function, survival, and NIV prevalence over time in ALS - a PRECISION ALS study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26 (sup1). pp. 61-72. ISSN 2167-8421

Iacoangeli, A. orcid.org/0000-0002-5280-5017, Dilliott, A.A., Al Khleifat, A. et al. (30 more authors) (2025) Oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling and therapeutic implications. Journal of Neurology, Neurosurgery & Psychiatry. ISSN 0022-3050

Saez-Atienzar, S., Souza, C.D.S., Chia, R. et al. (323 more authors) (2024) Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data. Cell Genomics, 4 (11). 100679. ISSN 2666-979X

Marriott, H. orcid.org/0000-0003-1231-2880, Spargo, T.P., Al Khleifat, A. orcid.org/0000-0002-7406-9831 et al. (26 more authors) (2024) Mutations in the tail and rod domains of the neurofilament heavy‐chain gene increase the risk of ALS. Annals of Clinical and Translational Neurology, 11 (7). pp. 1775-1786. ISSN 2328-9503

Taş, G. orcid.org/0009-0008-2409-0246, Westerdijk, T., Postma, E. et al. (87 more authors) (2024) Computing linkage disequilibrium aware genome embeddings using autoencoders. Bioinformatics, 40 (6). btae326. ISSN 1367-4803

Alarcan, H. orcid.org/0009-0002-8788-2773, Bruno, C., Emond, P. et al. (20 more authors) (2024) Pharmacometabolomics applied to low‐dose interleukin‐2 treatment in amyotrophic lateral sclerosis. Annals of the New York Academy of Sciences, 1536 (1). pp. 82-91. ISSN 0077-8923

Lombardo, F.L. orcid.org/0000-0001-6183-0735, Spila Alegiani, S., Mayer, F. et al. (93 more authors) (2023) A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. Trials, 24 (1). 792. ISSN 1468-6708

Gwathmey, K.G. orcid.org/0000-0002-7589-8826, Corcia, P., McDermott, C.J. orcid.org/0000-0002-1269-9053 et al. (4 more authors) (2023) Diagnostic delay in amyotrophic lateral sclerosis. European Journal of Neurology, 30 (9). pp. 2595-2601. ISSN 1351-5101

Van Daele, S.H. orcid.org/0000-0002-3005-3619, Moisse, M., van Vugt, J.J.F.A. orcid.org/0000-0002-4161-4004 et al. (31 more authors) (2023) Genetic variability in sporadic amyotrophic lateral sclerosis. Brain, 146 (9). pp. 3760-3769. ISSN 0006-8950

McFarlane, R., Galvin, M., Heverin, M. et al. (19 more authors) (2023) PRECISION ALS—an integrated pan European patient data platform for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24 (5-6). pp. 389-393. ISSN 2167-8421

Chen, Z., Reynolds, R.H., Pardiñas, A.F. et al. (23 more authors) (2023) The contribution of Neanderthal introgression and natural selection to neurodegenerative diseases. Neurobiology of Disease, 180. 106082. ISSN 0969-9961

Adey, B.N., Cooper-Knock, J., Al Khleifat, A. et al. (30 more authors) (2023) Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival. Frontiers in Cellular Neuroscience, 17. 1112405. ISSN 1662-5102

Al Khleifat, A., Iacoangeli, A., Jones, A.R. et al. (42 more authors) (2022) Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data. Frontiers in Cellular Neuroscience, 16. 1050596. ISSN 1662-5102

Mehta, P.R. orcid.org/0000-0002-0255-407X, Iacoangeli, A. orcid.org/0000-0002-5280-5017, Opie-Martin, S. et al. (31 more authors) (2022) The impact of age on genetic testing decisions in amyotrophic lateral sclerosis. Brain, 145 (12). pp. 4440-4447. ISSN 0006-8950

Opie-Martin, S., Iacoangeli, A., Topp, S.D. et al. (46 more authors) (2022) The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nature Communications, 13 (1). 6901. ISSN 2041-1723

Albanese, A., Ludolph, A.C., McDermott, C.J. orcid.org/0000-0002-1269-9053 et al. (7 more authors) (2022) Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: the TUDCA-ALS trial protocol. Frontiers in Neurology, 13. 1009113. ISSN 1664-2295

Hop, P.J. orcid.org/0000-0002-9007-7436, Zwamborn, R.A.J. orcid.org/0000-0003-3952-5042, Hannon, E. orcid.org/0000-0001-6840-072X et al. (151 more authors) (2022) Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 14 (633). eabj0264. ISSN 1946-6234

Al Khleifat, A., Iacoangeli, A., van Vugt, J.J.F.A. et al. (44 more authors) (2022) Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. npj Genomic Medicine, 7 (1). 8.

Moisse, M., Zwamborn, R.A.J., Vugt, J. et al. (33 more authors) (2021) The effect of SMN gene dosage on ALS risk and disease severity. Annals of Neurology, 89 (4). pp. 686-697. ISSN 0364-5134

Dewan, R. orcid.org/0000-0002-7611-7032, Chia, R. orcid.org/0000-0002-4709-7423, Ding, J. et al. (469 more authors) (2021) Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron, 109 (3). 448-460.e4. ISSN 0896-6273

van Eijk, R.P.A., Kliest, T., McDermott, C.J. orcid.org/0000-0002-1269-9053 et al. (12 more authors) (2020) TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21 (7-8). pp. 496-501. ISSN 2167-8421

Tazelaar, G.H.P., Boeynaems, S., De Decker, M. et al. (35 more authors) (2020) ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2 (2). fcaa064. ISSN 2632-1297

van den Berg, L.H., Sorenson, E., Gronseth, G. et al. (20 more authors) (2019) Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 92 (14). e1610-e1623. ISSN 0028-3878

Van Der Spek, R.A., Van Rheenen, W., Pulit, S.L. et al. (34 more authors) (2018) Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration , 19 (1-2). pp. 1-3. ISSN 2167-8421

Westeneng, H.-J., Debray, T.P.A., Visser, A.E. et al. (44 more authors) (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, 17 (5). pp. 423-433. ISSN 1474-4422

Al-Chalabi, A. orcid.org/0000-0002-4924-7712, Andersen, P.M., Chandran, S. et al. (38 more authors) (2017) July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18 (7-8). pp. 471-474. ISSN 2167-8421

McLaughlin, R.L., Schijven, D., van Rheenen, W. et al. (433 more authors) (2017) Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications, 8. 14774.